Trump Says Administration Is Pressuring Drugmakers to Split Childhood Vaccines Into Five Doses
The directive, if carried through, would require pharmaceutical manufacturers to reformulate approved vaccine products based on a causal claim between vaccines and autism that the scientific and...
President Donald Trump stated publicly on Friday that his administration is "demanding the drug companies" alter childhood vaccine formulations so that each individual shot carries a lower dose, with the explicit goal of reducing a purported link to autism. The statement was made during an Oval Office press conference, as reported by the Washington Examiner.
The scientific basis Trump cited, that vaccines cause or contribute to autism, has been examined and rejected across multiple peer-reviewed bodies of evidence. The Centers for Disease Control and Prevention, the American Academy of Pediatrics, and the Institute of Medicine (now the National Academy of Medicine) have each published findings concluding no causal relationship exists between childhood vaccine administration and autism spectrum disorder. The original 1998 Wakefield study that first proposed such a link was retracted by The Lancet in 2010 after investigators found data had been manipulated and the lead author had undisclosed financial conflicts.
Trump did not specify during the press conference which agency would carry out the directive, whether the Food and Drug Administration or the Department of Health and Human Services would issue formal guidance, or whether the demand is being communicated through regulatory rulemaking, informal agency pressure, or direct executive instruction to manufacturers. The mechanism by which the administration intends to compel reformulation is not stated in available public records as of September 18, 2026.
Vaccine approvals are governed under the Federal Food, Drug, and Cosmetic Act. Any change to an approved vaccine's dosage, formulation, or schedule requires a biologics license amendment reviewed by the FDA's Center for Biologics Evaluation and Research. Whether such a process has been formally initiated is not reflected in publicly available FDA docket records as of the date of this publication. A formal rulemaking filing, if one has been submitted, would be the document that would reveal the administration's legal pathway.
The affected manufacturers would include the primary suppliers of combination childhood vaccines in the United States. Pfizer, Merck, and Sanofi together hold the major biologics licenses for vaccines on the CDC's childhood immunization schedule, according to FDA licensing records. None of the three companies have made public statements responding to Trump's Friday remarks, as of September 18, 2026.
The current childhood immunization schedule, recommended by the CDC's Advisory Committee on Immunization Practices and last updated in February 2026, groups several antigens into combination shots, such as DTaP, which covers diphtheria, tetanus, and pertussis in a single administration. Splitting those combinations into five separate doses would change both the manufacturing specifications and the clinical administration schedule for pediatricians across the country.
The American Academy of Pediatrics has not issued a formal statement in response to Friday's remarks as of publication time. The CDC's public communications on the childhood vaccine schedule have not been updated since Trump's statement.
The political context includes Trump's longstanding personal association with vaccine skepticism, which predates his presidency. He raised concerns about vaccine-autism links in campaign statements during his 2016 run, and appointed Robert F. Kennedy Jr. As Secretary of Health and Human Services in early 2025. Kennedy has publicly questioned the safety of several approved vaccines over many years. Kennedy's role in shaping any forthcoming regulatory action has not been confirmed in any HHS filing or public record available at this time.
This development follows the administration's broader pattern of directing health agencies toward policy reviews outside standard notice-and-comment rulemaking. As previously reported, RFK Jr.-Linked Nonprofit Sold Access to HHS Officials, Report Says, raising questions about the advisory channels informing HHS policymaking.
Congress has not yet responded to Friday's statement through any committee hearing, resolution, or floor statement entered into the Congressional Record as of September 18, 2026. The Senate Health, Education, Labor, and Pensions Committee and the House Energy and Commerce Committee both hold jurisdiction over FDA regulatory authority and could request briefings or compel testimony on any forthcoming vaccine reformulation directive.
What remains unknown: whether a formal regulatory filing has been submitted to the FDA; whether the administration has issued written guidance to manufacturers outside of public channels; and whether any manufacturer has received a written demand letter from a federal agency. A Freedom of Information Act request directed to HHS and FDA, or a formal congressional inquiry, would be the documents most likely to resolve those questions.